Objectives: The aim of the study was to define the maximum tolerated dose (MTD) of the combination of raltitrexed plus carmofur, and to evaluate the tolerability and efficacy of this combination in metastatic colorectal cancer. Methods: Twenty-eight patients (23 receiving first-line therapy, 5 receiving second-line therapy) entered the study; 16 were chemonaive. Raltitrexed (Tomudex) 1.5–3.0 mg/m2 was given as a 15- to 30-min intravenous infusion on day 1 of a 21-day cycle followed by carmofur 300–400 mg/m2 orally 3 times daily on days 2–14. Therapy was given until disease progression or dose-limiting toxicity (DLT) occurred. Results: A total of 170 cycles of therapy were administered. The MTD was reached at the raltitrexed dose of 3.0 mg/m2 and the carmofur dose of 400 mg/m2. DLTs included grade 3–4 diarrhea, fatigue, anorexia, mucositis, anemia, thrombocytopenia, neutropenia, neurological symptoms and febrile neutropenia. Eleven of the 22 evaluable first-line patients achieved a partial response (response rate 50%, 95% confidence interval 29–71%), 8 had stable disease and 3 had disease progression. One of the 5 patients who received second-line therapy responded. Conclusions: The recommended dose of this combination therapy for further evaluation is raltitrexed 3.0 mg/m2 plus carmofur 300 mg/m2. This combination has unique but manageable toxicity and promising efficacy in metastatic colorectal cancer.

Keywords:
Colorectal cancer, Chemotherapy, Raltitrexed, Carmofur
1.
Scheithauer W, Rosen H, Kornek GV, Sebesta C, Depisch D: Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer. BMJ 1993;306:752–755.
2.
Glimelius B, Hoffman K, Graf W, Haglund U, Nyren O, Pahlman L, Sjoden PO: Cost-effectiveness of palliative chemotherapy in advanced gastrointestinal cancer. Ann Oncol 1995;6:267–274.
3.
Pazdur R, Lassere Y, Rhodes V, Ajani JA, Sugarman SM, Patt YZ, Jones DV Jr, Markowitz AB, Abbruzzese JL, Bready B: Phase II trial of uracil and tegafur plus oral leucovorin: An effective oral regimen in the treatment of metastatic colorectal carcinoma. J Clin Oncol 1994;12:2296–2300.
4.
Ito K, Yamaguchi A, Miura K, Kato T, Baba S, Matsumoto S, Ishii M, Tagaki H: Oral adjuvant chemotherapy with carmofur (HCFU) for colorectal cancer: Five-year follow-up. Tokai HCFU Study Group – third study on colorectal cancer. J Surg Oncol 1996;63:107–111.
5.
Nogue M, Segui MA, Saigi E, Batiste-Alentorn E, Arcusa A, Boleda M, Anton I: Protracted treatment with tegafur and low dose oral leucovorin in patients with advanced colorectal carcinoma. Cancer 1998;83:254–258.
6.
Sakamoto J, Hamada C, Kodaira S, Nakazato H, Ohashi Y: Adjuvant therapy with oral fluoropyrimidines as main chemotherapeutic agents after curative resection for colorectal cancer: Individual patient data meta-analysis of randomized trials. Jpn J Clin Oncol 1999;29:78–86.
7.
Koyama Y, Koyama Y: Phase I study of a new antitumor drug, 1-hexylcarbamoyl-5-fluorouracil (HCFU), administered orally: An HCFU clinical study group report. Cancer Treat Rep 1980;64:861–867.
8.
Koyama Y, Inokuchi K, Koyama Y: Absorption and excretion of a new oral antitumor drug, 1-hexylcarbamoyl-5-fluorouracil (HCFU) in cancer patients. Jpn J Clin Oncol 1980;10:83–92.
9.
Koyama Y: 1-Hexylcarbamoyl-5-fluorouracil (HCFU) – a masked 5-fluorinated pyrimidine. Cancer Treat Rev 1981;8:147–156.
10.
Koyama Y: Phase II study of carmofur (HCFU) fine granules (in Japanese). Gan To Kagaku Ryoho 1982;9:906–914.
11.
Sakurai Y: Studies of analogues of fluorinated pyrimidines in Japan; in Carter FC, Sakurai Y, Umezawa H (eds): New Drugs in Cancer Chemotherapy. Berlin, Springer, 1981, pp 91–99.
12.
Grohn P, Heinonen E, Kumpulainen E, Lansimies H, Lantto A, Salmi R, Pyrhonen S, Numminen S: Oral carmofur in advanced gastrointestinal cancer. Am J Clin Oncol 1990;13:477–479.
13.
Takashima S, Kinami Y, Kiriyama M, Tomita F, Tomita F, Ueno K, Miyazaki I: Distribution of 1-hexylcarbamoyl-5-fluorouracil in rats and human patients, and clinical results in patients with colorectal cancer (in Japanese). Gan To Kagaku Ryoho 1986;13:549–555.
14.
Nishio S, Kishimoto T, Maekawa M, Morikawa Y, Funai K, Hayahara N, Yuki K, Nishijima T, Yasumoto R, et al: Study on effectiveness of carmofur (Mifurol) in urogenital carcinoma, especially bladder cancer, as a post-operative adjuvant chemotherapeutic agent (in Japanese). Hinyokika Kiyo 1987;33:295–303.
15.
Kusama M, Tominaga T, Enomoto K, Yoshida M, Koyama H, Sonoo H, Takashima S, Abe R, Nishi T, Yamaguchi S, et al: Clinical effects of carmofur (Mifurol) on advanced and recurrent breast cancer in a cooperative study. Research association for re-evaluation of direct effects of Mifurol on breast cancer (in Japanese). Gan To Kagaku Ryoho 1995;22:467–475.
16.
Kajanti MJ, Pyrhönen SO: Phase II trial of oral carmofur in advanced pancreatic carcinoma. Ann Oncol 1991;2:765–766.
17.
Yasue M, Ishijima B, Sato J, Mizutani T, Morimatsu Y: A case of toxic leucoencephalopathy induced by 5FU derivatives (in Japanese). No Shinkei Geka 1985;13:1229–1234.
18.
Furuya A, Shiroyama H, Yano Y, Kishida S, Okeda R: Report on an autopsy of a patient with carmofur (HCFU) leukoencephalopathy (in Japanese). Rinsho Shinkeigaku 1987;27:1430–1440.
19.
Cunningham D, Zalcberg JR, Rath U, Oliver I, van Cutsem E, Svensson C, Seitz JF, Harper P, Kerr D, Perez-Manga G: Final results of a randomised trial comparing ‘Tomudex’ (raltitrexed) with 5-fluorouracil plus leucovorin in advanced colorectal cancer. ‘Tomudex’ Colorectal Cancer Study Group. Ann Oncol 1996;7:961–965.
20.
Pazdur R, Vincent M: Raltitrexed (Tomudex®) versus 5-fluorouracil and leucovorin (5-FU + LV) in patients with advanced colorectal cancer (ACC): Results of a randomized, multicenter North American trial (abstract 801). Proc Am Soc Clin Oncol 1997;16:228a.
21.
Cocconi G, Cunningham D, van Cutsem E, Francois E, Gustavsson B, van Hazel G, Kerr D, Possinger K, Hietschold SM: Open, randomized multicenter trial of raltitrexed versus fluorouracil plus high-dose leucovorin in patients with advanced colorectal cancer. J Clin Oncol 1998;16:2943–2952.
22.
Jackman AL, Kimbell R, Ford HER: Combination of raltitrexed with other cytotoxic agents: Rationale and preclinical observations. Eur J Cancer 1999;35(suppl 1):S3–S8.
23.
Johnston P, Behan KA, Allegra CJ, Drake JC: Fluorouracil: Active in ZD1694 (tomudex)-resistant cell lines with markedly elevated thymidylate synthase levels. J Natl Cancer Inst 1995;87:1558–1559.
24.
Yan JM, Lu ZH, Shao LN, Diasio RB: The effect of ‘Tomudex’ on dihydropyrimidine dehydrogenase activity (abstract 4133). Proc Am Assoc Cancer Res 1997;38:615.
25.
Schwartz GK, Harstrick A, González Barón M: Raltitrexed (Tomudex) in combination with 5-fluorouracil for the treatment of patients with advanced colorectal cancer: Preliminary results from phase I clinical trials. Eur J Cancer 1999;35(suppl 1):S9–S13.
26.
Miller AB, Hoogstraten B, Staquet M, Winkler A: Reporting results of cancer treatment. Cancer 1981;47:207–214.
27.
Clarke JS, Ward J, de Boer M, Planting A, Verweij J, Sutcliffe F, Azab M, Judson IR: Phase I study of the new thymidylate synthetase inhibitor ‘Tomudex’ (ZD 1694) in advanced malignancy (abstract 240). Ann Oncol 1994;5:132.
28.
Sobrero AF: The potential role of Tomudex in the treatment of advanced colorectal cancer. Tumori 1997;83:576–580.
29.
Sawada M, Matsui Y, Okudaira Y: Concentrations of a new antitumor agent, 1-hexylcarbamoyl-5-fluorouracil in serum and gynecologic tumor tissue. Nippon Sanka Fujinka Gakkai Zasshi 1983;35:2421–2426.
30.
Cunningham D: Mature results from three large controlled studies with raltitrexed (‘Tomudex’). Br J Cancer 1998;77(suppl 2):15–21.
31.
Österlund P, Elomaa I, Alaluhtala T, Orpana A, Joensuu H: A syndrome characterized by fever, fatigue, and flu-like symptoms associated with raltitrexed therapy (abstract 1135). Proc Am Soc Clin Oncol 1999;18:296a.
32.
De Gramont A, Figer A, Seymour M, Homerin M, leBail N, Cassidy J, Boni C, Cortes-Funes H, Freyer G, Hendler D, Louve C: A randomized trial of leucovorin (LV) and 5-fluorouracil (5FU) with or without oxaliplatin in advanced colorectal cancer (abstract 985). Proc Am Soc Clin Oncol 1998;17:257a.
33.
Saltz LB, Locker PK, Pirotta N, Elfring GL, Miller LL: Weekly irinotecan (CPT-11), leucovorin (LV), and fluorouracil (FU) is superior to daily X5 LV/FU in patients (pts) with previously untreated metastatic colorectal cancer (CRC) (abstract 898). Proc Am Soc Clin Oncol 1999;18:233a.
34.
Douillard JY, Cunningham D, Roth AD, Germa JR, Jarnes RD, Karasek P, Jandik P, Iveson T, Carmichael J, Gruia G, Dernbak M, Sibaud D, Rougier P: A randomized phase III trial comparing irinotecan (IRI) + 5FU/folinic acid (FA) to the same schedule of 5FU/FA in patients (pts) with metastatic colorectal cancer (MCRC) as front line chemotherapy (CT) (abstract 899). Proc Am Soc Clin Oncol 1999;18:233a.
© 2001 S. Karger AG, Basel
2001
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.